Roche-Spark deal review in U.K. unnerves M&A watchers—and they were spooked already

When it comes to highly publicized M&A deals, no marriage has been more delayed—and scrutinized—than Roche’s pending $4.8 billion pick up of Spark Therapeutics. So much so that even a small administrative advance in the UK has triggered headlines.